China's State Council Issues Guidelines on Innovative Drug Pricing
China's State Council has released new guidelines aimed at supporting innovative drug pricing through value-based methods while reducing generic drug prices via market competition. A Citigroup analyst described the guidelines as the most significant in a decade.
Substrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)China's State Council published guidelines this month on pricing for innovative drugs, according to a South China Morning Post report. The guidelines support patented innovative drugs with value-based pricing and aim to lower generic drug prices through market competition and volume-based procurement.
Volume-based procurement involves the government purchasing drugs in bulk for public hospitals, which has placed price and competitive pressure on multinational companies.
The policy permits biotech companies to set higher prices in the private market, including private hospitals, retail pharmacies, and online platforms. It also encourages commercial insurance to take a larger role in funding innovative drugs.
John Yung, head of Asia healthcare research at Citigroup, stated in an April 16 research report that the guidelines provide more profitable channels for innovative drugmakers. He noted potential benefits for internet healthcare players, pharmacies, and private healthcare services, mentioning examples such as Alibaba Health, Yifeng, and Hygeia.
Key Facts
Story Timeline
3 events- 2026-04-22
South China Morning Post reported on China's State Council guidelines for innovative drug pricing.
1 sourceSouth China Morning Post - 2026-04-16
Citigroup released a research report assessing the guidelines' benefits for drugmakers and related sectors.
1 sourceSouth China Morning Post - April 2026
China's State Council published the framework document on innovative drug pricing.
1 sourceSouth China Morning Post
Potential Impact
- 01
Generic drug prices in public hospitals could decrease due to volume-based procurement.
- 02
Multinational pharmaceutical companies may experience reduced pricing pressure in China.
- 03
Domestic biotech firms could see increased profitability through private market channels.
- 04
Internet healthcare and pharmacy services may gain from expanded innovative drug access.
Transparency Panel
Related Stories
koreaherald.comJudge in Kim Keon Hee Corruption Appeal Found Dead Near Seoul High Court
The presiding judge in the appeals trial of former South Korean first lady Kim Keon Hee was discovered dead near the Seoul High Court early Wednesday. Police are investigating the incident as a possible suicide after finding a note at the scene. The death follows the court's rece…
Substrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)Survey Shows Most Israelis Oppose Ending Iran Conflict Under Current Terms
A survey by the Israel Democracy Institute indicates that 59 percent of Israelis oppose ending the ongoing conflict with Iran at this stage. Iranian Foreign Minister Abbas Araghchi visited China amid regional tensions and ahead of U.S. President Donald Trump's planned trip to Bei…
news.sky.comFrench Cargo Ship Hit by Missile in Gulf Region, Injuring Filipino Crew
A French-owned cargo ship was struck by a cruise missile in the Gulf region, resulting in injuries to several Filipino crew members. U.S. officials attributed the attack to Iran, according to CBS reports. Three additional incidents have been reported in the area since the strike.